CHROMID® CPS® Elite agar/Columbia CNA agar + 5% sheep blood (CPSE/CNA) - This product consists of two culture media, - BIOMERIEUX SA

Duns Number:276816717

Device Description: This product consists of two culture media, dispensed into one Petri dish containing separ This product consists of two culture media, dispensed into one Petri dish containing separate compartments. It is intended for use with urine specimens

Want to know more about this Product? Request more information now!


More Product Details

Catalog Number

-

Brand Name

CHROMID® CPS® Elite agar/Columbia CNA agar + 5% sheep blood (CPSE/CNA)

Version/Model Number

CHROMID® CPS® Elite agar/Columbia CNA agar + 5% sheep blood (CPSE/CNA)

Device Commercial Distribution Status

In Commercial Distribution

Commercial Distribution End Date

-

Issuing Agency

In GS1

Product Characteristics

MRI safety Status

Labeling does not contain MRI Safety Information

Device required to be labeled as containing natural rubber latex or dry natural rubber (21 CFR 801.437)

-

Device labeled as "Not made with natural rubber latex"

-

For Single-Use

Yes

Prescription Use (Rx)

Yes

Over the Counter (OTC)

-

Kit

-

Combination Product

-

Human Cell, Tissue or Cellular or Tissue-Based Product (HCT/P)

-

FDA Premarket Submission

-

Product Code Details

Product Code

JXA

Product Code Name

KIT, SCREENING, URINE

Device Record Status

Public Device Record Key

f2aec207-bdab-4aa2-9de4-48d76e00dcaf

Public Version Date

May 27, 2020

Public Version Number

1

DI Record Publish Date

May 19, 2020

Additional Identifiers

Package DI Number

03573026468545

Quantity per Package

2

Contains DI Package

03573026600426

Package Discontinue Date

-

Package Status

In Commercial Distribution

Package Type

-

"BIOMERIEUX SA" Characteristics
Device Class Device Class Description No of Devices
1 A medical device with low to moderate risk that requires general controls 82
2 A medical device with a moderate to high risk that requires special controls. 156
3 A medical device with high risk that requires premarket approval 3